These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 24270404)
1. Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Merli M; Visco C; Spina M; Luminari S; Ferretti VV; Gotti M; Rattotti S; Fiaccadori V; Rusconi C; Targhetta C; Stelitano C; Levis A; Ambrosetti A; Rossi D; Rigacci L; D'Arco AM; Musto P; Chiappella A; Baldini L; Bonfichi M; Arcaini L Haematologica; 2014 Mar; 99(3):489-96. PubMed ID: 24270404 [TBL] [Abstract][Full Text] [Related]
2. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Ennishi D; Maeda Y; Niitsu N; Kojima M; Izutsu K; Takizawa J; Kusumoto S; Okamoto M; Yokoyama M; Takamatsu Y; Sunami K; Miyata A; Murayama K; Sakai A; Matsumoto M; Shinagawa K; Takaki A; Matsuo K; Kinoshita T; Tanimoto M Blood; 2010 Dec; 116(24):5119-25. PubMed ID: 20823454 [TBL] [Abstract][Full Text] [Related]
3. Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana Linfomi. Arcari A; Tabanelli V; Merli F; Marcheselli L; Merli M; Balzarotti M; Zilioli VR; Fabbri A; Cavallo F; Casaluci GM; Tucci A; Puccini B; Pennese E; Di Rocco A; Zanni M; Flenghi L; Gini G; Sartori R; Chiappella A; Usai SV; Tani M; Marino D; Arcaini L; Vallisa D; Spina M Br J Haematol; 2023 May; 201(4):653-662. PubMed ID: 36733229 [TBL] [Abstract][Full Text] [Related]
4. Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study. Carella AM; de Souza CA; Luminari S; Marcheselli L; Chiappella A; di Rocco A; Cesaretti M; Rossi A; Rigacci L; Gaidano G; Merli F; Spina M; Stelitano C; Hohaus S; Barbui A; Puccini B; Miranda EC; Guida A; Federico M Leuk Lymphoma; 2013 Jan; 54(1):53-7. PubMed ID: 22712840 [TBL] [Abstract][Full Text] [Related]
5. Hepatitis C Virus Infection and Treatment as Independent Prognostic Factors in Diffuse Large B-Cell Lymphoma Egyptian Patients. Elbedewy TA; Elashtokhy HEA; Abd-Elsalam S; Suliman MA Curr Cancer Drug Targets; 2020; 20(8):638-645. PubMed ID: 32392114 [TBL] [Abstract][Full Text] [Related]
6. Role of virological serum markers in patients with both hepatitis B virus infection and diffuse large B-cell lymphoma. Zhou X; Wuchter P; Egerer G; Kriegsmann M; Mataityte A; Koelsche C; Witzens-Harig M; Kriegsmann K Eur J Haematol; 2019 Oct; 103(4):410-416. PubMed ID: 31338887 [TBL] [Abstract][Full Text] [Related]
7. Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era. Zaky AH; Bakry R; El-sayed MI; Elwanis MA; Nabih O Hematology; 2014 Oct; 19(7):412-6. PubMed ID: 24620947 [TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Go SI; Park MJ; Song HN; Kim HG; Kang MH; Lee HR; Kim Y; Kim RB; Lee SI; Lee GW J Cachexia Sarcopenia Muscle; 2016 Dec; 7(5):567-576. PubMed ID: 27104110 [TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of hepatitis C virus infection in patients with diffuse large B-cell lymphoma treated with immunochemotherapy in the context of a novel prognostic index. Chen YY; Huang CE; Liang FW; Lu CH; Chen PT; Lee KD; Chen CC Cancer Epidemiol; 2015 Jun; 39(3):382-7. PubMed ID: 25899771 [TBL] [Abstract][Full Text] [Related]
10. Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Dlouhy I; Torrente MÁ; Lens S; Rovira J; Magnano L; Giné E; Delgado J; Balagué O; Martínez A; Campo E; Forns X; Sánchez-Tapias JM; López-Guillermo A Ann Hematol; 2017 Mar; 96(3):405-410. PubMed ID: 28035434 [TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of serum aspartic transaminase in diffuse large B-cell lymphoma. Lu TX; Wu S; Cai DY; Hong TT; Zhang Y; Gao HQ; Hua HY; Wu XH BMC Cancer; 2019 Jun; 19(1):553. PubMed ID: 31176361 [TBL] [Abstract][Full Text] [Related]
12. Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi. Merli F; Luminari S; Rossi G; Mammi C; Marcheselli L; Ferrari A; Spina M; Tucci A; Stelitano C; Capodanno I; Fragasso A; Baldini L; Bottelli C; Montechiarello E; Fogazzi S; Lamorgese C; Cavalli L; Federico M; Leuk Lymphoma; 2014 Jan; 55(1):38-43. PubMed ID: 23517562 [TBL] [Abstract][Full Text] [Related]
13. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study. Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932 [TBL] [Abstract][Full Text] [Related]
14. High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. Cardesa-Salzmann TM; Colomo L; Gutierrez G; Chan WC; Weisenburger D; Climent F; González-Barca E; Mercadal S; Arenillas L; Serrano S; Tubbs R; Delabie J; Gascoyne RD; Connors JM; Mate JL; Rimsza L; Braziel R; Rosenwald A; Lenz G; Wright G; Jaffe ES; Staudt L; Jares P; López-Guillermo A; Campo E Haematologica; 2011 Jul; 96(7):996-1001. PubMed ID: 21546504 [TBL] [Abstract][Full Text] [Related]
15. Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience. Nishikawa H; Tsudo M; Osaki Y Oncol Rep; 2012 Sep; 28(3):835-40. PubMed ID: 22736295 [TBL] [Abstract][Full Text] [Related]
16. Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era. Cheng CL; Huang SC; Chen JH; Wei CH; Fang WQ; Su TH; Yuan CT; Liu JH; Chuang MK; Tien HF Oncologist; 2020 Sep; 25(9):793-802. PubMed ID: 32275807 [TBL] [Abstract][Full Text] [Related]
17. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma]. Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579 [No Abstract] [Full Text] [Related]
18. Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL). Tucci A; Merli F; Fabbri A; Marcheselli L; Pagani C; Puccini B; Marino D; Zanni M; Pennese E; Flenghi L; Arcari A; Botto B; Celli M; Mammi C; Re A; Campostrini G; Tafuri A; Zilioli VR; Cencini E; Sartori R; Bottelli C; Merli M; Petrucci L; Gini G; Balzarotti M; Cavallo F; Musuraca G; Luminari S; Rossi G; Spina M Haematologica; 2023 Apr; 108(4):1083-1091. PubMed ID: 36384247 [TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment. Visco C; Finotto S World J Gastroenterol; 2014 Aug; 20(32):11054-61. PubMed ID: 25170194 [TBL] [Abstract][Full Text] [Related]
20. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era. Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]